Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 9/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204818 | 0.90 | DUT (0.44) | DUTROCK2BRD4NAMPTDDB1 | |
| SCHEMBL21536687 | 0.87 | DUT (0.49) | DUTROCK2 | |
| SCHEMBL21536738 | 0.84 | DUT (0.42) | DUTROCK2BRD4DDB1CRBN | |
| SCHEMBL21536576 | 0.83 | DUT (0.49) | DUTNAMPT | |
| SCHEMBL21536578 | 0.83 | KAT6A (0.43) | DUTBRD4DDB1CRBNPGR | |
| SCHEMBL20204876 | 0.80 | DUT (0.60) | DUT | |
| SCHEMBL27991137 | 0.80 | F2 (0.56) | DUTBRD4PGRF2 | |
| SCHEMBL20204819 | 0.78 | ROCK2 (0.45) | DUTROCK2 | |
| SCHEMBL21536579 | 0.78 | DUT (0.47) | DUTROCK2DDB1CRBN | |
| SCHEMBL21536069 | 0.75 | ROCK2 (0.42) | DUTROCK2BRD4DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| WO-2021263205-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | DUT 2/4885ROCK2 3018/4885BRD4 1293/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DUT 3/4885ROCK2 4782/4885BRD4 922/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | DUT 3/4885ROCK2 4782/4885BRD4 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.